{"id":7322,"date":"2023-03-20T09:12:46","date_gmt":"2023-03-20T08:12:46","guid":{"rendered":"https:\/\/leo-foundation.org\/en\/?p=7322"},"modified":"2023-03-20T13:08:39","modified_gmt":"2023-03-20T12:08:39","slug":"annual-report-2022-a-year-of-transition-across-the-leo-foundation","status":"publish","type":"post","link":"https:\/\/leo-foundation.org\/en\/2023\/03\/20\/annual-report-2022-a-year-of-transition-across-the-leo-foundation\/","title":{"rendered":"Annual Report 2022: A year of transition across the LEO Foundation"},"content":{"rendered":"\n
20 March 2023<\/em><\/p>\n\n\n\n 2022 was a year of transition across the activities of the LEO Foundation: the research we support, the company we own, the financial investments we make, and our cultural and historical endeavors. Adapting to a changing world and taking action to fulfill our commitment to improve the lives of people living with skin diseases were at the very core of the transition.<\/strong><\/strong><\/strong><\/p>\n\n\n\n Our philanthropic activities continued the transition in line with our ambitious new grant strategy, which supports science to improve our understanding of the skin and its diseases; our financial investments evolved in line with macroeconomic and geopolitical changes; and transition efforts at LEO Pharma kept the company on track to deliver on its growth ambitions.<\/p>\n\n\n\n 2022 highlights:<\/strong><\/p>\n\n\n\n